Consun Pharmaceutical Group Ltd. Annual Results: Standalone & Consolidated Reports

Annual Results

Results Snapshot

Figures in Million

Consolidate Annual Results

Dec'24

Dec'23

Dec'22

Dec'21

Dec'20

Dec'19

Dec'18

Net Sales

3,217.15

2,862.07

2,720.73

2,464.25

1,969.64

1,959.70

2,184.10

Other Operating Income

0.00

Total Operating income

3,217.15

2,862.07

2,720.73

2,464.25

1,969.64

1,959.70

2,184.10

Raw Material Cost

786.21

738.62

670.68

623.48

484.49

529.37

544.31

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

643.13

534.28

518.26

441.10

319.06

345.56

340.48

Power Cost

0.00

Manufacturing Expenses

26.98

23.50

12.71

15.55

24.05

32.93

32.54

Selling and Distribution Expenses

1,287.11

1,156.57

1,098.26

939.82

777.26

788.82

793.73

Other Expenses

-56.44

-43.78

-39.43

-33.35

-24.91

-29.30

-29.26

Total Expenditure (Excl Depreciation)

2,179.08

2,015.13

1,905.62

1,686.43

1,355.76

1,403.66

1,418.52

Operating Profit (PBDIT) excl Other Income

1038.1

846.9

815.1

777.8

613.9

556

765.6

Other Income

95.01

130.94

65.57

76.39

66.10

-1.73

-2.60

Operating Profit (PBDIT)

1,201.93

1,063.63

968.90

941.58

760.07

636.59

843.18

Interest

26.98

23.50

12.71

15.55

24.05

32.93

32.54

Exceptional Items

0.00

-369.81

0.00

Gross Profit (PBDT)

2,430.94

2,123.45

2,050.05

1,840.76

1,485.15

1,430.33

1,639.79

Depreciation

68.85

85.74

88.22

87.36

80.08

82.28

80.20

Profit Before Tax

1,106.09

954.39

867.96

838.66

655.94

151.56

730.45

Tax

111.38

85.25

72.91

131.06

114.61

79.99

141.20

Provisions and contingencies

0.00

Profit After Tax

987.14

866.91

794.14

711.28

560.48

90.51

551.19

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

987.14

866.91

794.14

711.28

560.48

90.51

551.19

Share in Profit of Associates

0.00

Minority Interest

7.50

2.23

0.92

-3.68

-19.15

-18.93

38.07

Other related items

0.00

Consolidated Net Profit

994.64

869.14

795.06

707.60

541.33

71.58

589.26

Equity Capital

0.00

Face Value

0.0

Reserves

4,360.72

3,992.80

3,531.17

3,202.15

2,632.56

2,230.57

2,460.00

Earnings per share (EPS)

1.19

1.08

1.0

0.88

0.69

0.11

0.63

Diluted Earnings per share

1.19

1.08

1.0

0.88

0.69

0.11

0.63

Operating Profit Margin (Excl OI)

32.27%

29.59%

29.96%

31.56%

31.17%

28.37%

35.05%

Gross Profit Margin

36.52%

36.34%

35.14%

37.58%

37.37%

11.93%

37.12%

PAT Margin

30.68%

30.29%

29.19%

28.86%

28.46%

4.62%

25.24%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Annual Analysis Highlights

Net Sales

YoY Growth in year ended Dec 2024 is 12.40% vs 5.20% in Dec 2023

Consolidate Net Profit

YoY Growth in year ended Dec 2024 is 14.44% vs 9.31% in Dec 2023

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2024 is 18.68% vs 3.25% in Dec 2023

Interest

YoY Growth in year ended Dec 2024 is 14.89% vs 85.04% in Dec 2023

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2024 has improved from Dec 2023

Compare Annual Results Of Consun Pharmaceutical Group Ltd. With

Select Peers

Figures in Million

Consolidate Annual Results

Change(HKD)

Change(%)

Net Sales

3,217.15

6,955.50

-3,738.35

-53.75%

Other Operating Income

0.00

Total Operating income

3,217.15

6,955.50

-3,738.35

-53.75%

Raw Material Cost

786.21

1,446.24

-660.03

-45.64%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

643.13

881.17

-238.04

-27.01%

Power Cost

0.00

Manufacturing Expenses

26.98

251.27

-224.29

-89.26%

Selling and Distribution Expenses

1,287.11

2,143.12

-856.01

-39.94%

Other Expenses

-56.44

-92.00

35.56

38.65%

Total Expenditure (Excl Depreciation)

2,179.08

3,801.84

-1,622.76

-42.68%

Operating Profit (PBDIT) excl Other Income

1,038.07

3,153.66

-2,115.59

-67.08%

Other Income

95.01

48.02

46.99

97.86%

Operating Profit (PBDIT)

1,201.93

3,634.97

-2,433.04

-66.93%

Interest

26.98

251.27

-224.29

-89.26%

Exceptional Items

0.00

-600.30

600.30

100.00%

Gross Profit (PBDT)

2,430.94

5,509.26

-3,078.32

-55.88%

Depreciation

68.85

433.29

-364.44

-84.11%

Profit Before Tax

1,106.09

2,350.11

-1,244.02

-52.93%

Tax

111.38

299.39

-188.01

-62.80%

Provisions and contingencies

0.00

Profit After Tax

987.14

2,201.85

-1,214.71

-55.17%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

987.14

2,201.85

-1,214.71

-55.17%

Share in Profit of Associates

0.00

Minority Interest

7.50

-151.16

158.66

104.96%

Other related items

0.00

Consolidated Net Profit

994.64

2,050.68

-1,056.04

-51.50%

Equity Capital

0.00

Face Value

0.00

Reserves

4,360.72

8,737.04

-4,376.32

-50.09%

Earnings per share (EPS)

1.19

2.50

-1.31

-52.40%

Diluted Earnings per share

1.19

2.50

-1.31

-52.40%

Operating Profit Margin (Excl OI)

32.27%

45.34%

0.00

-13.07%

Gross Profit Margin

36.52%

40.02%

0.00

-3.50%

PAT Margin

30.68%

31.66%

0.00

-0.98%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Annual - Net Sales

Net Sales 321.71 Million

in Dec 2024

Figures in Million

YoY Growth in year ended Dec 2024 is 12.40% vs 5.20% in Dec 2023

Annual - Consolidate Net Profit

Consolidate Net Profit 99.46 Million

in Dec 2024

Figures in Million

YoY Growth in year ended Dec 2024 is 14.44% vs 9.31% in Dec 2023

Annual - Operating Profit (PBDIT)

Operating Profit (PBDIT) 110.69 Million

in Dec 2024

Figures in Million

YoY Growth in year ended Dec 2024 is 18.68% vs 3.25% in Dec 2023

Annual - Interest

Interest 2.70 Million

in Dec 2024

Figures in Million

YoY Growth in year ended Dec 2024 is 14.89% vs 85.04% in Dec 2023

Annual - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 32.27%

in Dec 2024

Figures in %

YoY Growth in year ended Dec 2024 has improved from Dec 2023